Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy (Q38502148)

3 September 2017

1 reference

title

Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy (English)

1 reference

3 September 2017

0 references

1 reference

2

Henry Krum

1 reference

3 September 2017

Richard E Gilbert

1

1 reference

PubMed ID

26009231

3 September 2017

language of work or name

English

0 references

publication date

1 May 2015

1 reference

3 September 2017

1 reference

3 September 2017

385

1 reference

3 September 2017

2107-2117

1 reference

3 September 2017

9982

1 reference

Role of diabetes in congestive heart failure: the Framingham study

3 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

The incidence of congestive heart failure in type 2 diabetes: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Changes in diabetes-related complications in the United States, 1990-2010

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Heart failure: the frequent, forgotten, and often fatal complication of diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Demographics and concomitant disorders in heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Are β-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Cardiac resynchronization therapy improves heart rate profile and heart rate variability of patients with moderate to severe heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Effect of diabetes mellitus on formation of coronary collateral vessels

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic States: a possible explanation for impaired collateral formation in cardiac tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Impaired collateral vessel development in diabetes: potential cellular mechanisms and therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

The progression from hypertension to congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Myocardial cell death in human diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Relationships among natriuresis, atrial natriuretic peptide and insulin in insulin-dependent diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Intensive glucose control and macrovascular outcomes in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

An unexpected inverse relationship between HbA1c levels and mortality in patients with diabetes and advanced systolic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Relation between hemoglobin a(1c) and outcomes in heart failure patients with and without diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Diabetic retinopathy after two years of intensified insulin treatment. Follow-up of the Kroc Collaborative Study. The Kroc Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

The rise and fall of rosiglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Thiazolidinediones and Heart Failure: A teleo-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Role of renal proximal tubule transport in thiazolidinedione-induced volume expansion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Plasma concentrations of vascular endothelial growth factor are associated with peripheral oedema in patients treated with thiazolidinedione

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Sympathetic mechanisms of hypoglycemic counterregulation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Sitagliptin augments sympathetic enhancement of the renovascular effects of angiotensin II in genetic hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Effects of insulin on kidney function and sodium excretion in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Insulin and renal sodium retention in obese adolescents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Relationship between insulin release, antinatriuresis and hypokalaemia after glucose ingestion in normal and hypertensive man.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Effect of insulin on renal sodium and uric acid handling in essential hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Role of hyperglycemia and insulin resistance in determining sodium retention in non-insulin-dependent diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Insulin binding sites in various segments of the rabbit nephron

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Characterization of the regulation of renal Na+/H+ exchanger NHE3 by insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Regulation of the renal Na-HCO3 cotransporter: IX. Modulation by insulin, epidermal growth factor and carbachol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Tubular effects of insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Insulin resistance, obesity, hypertension, and renal sodium transport

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Epithelial Na+ channel (ENaC), hormones, and hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Predictors of mortality and morbidity in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Insulin-treated type 2 diabetes is associated with a decreased survival in heart failure patients after cardiac resynchronization therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

The incidence of congestive heart failure associated with antidiabetic therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Pioglitazone initiation and subsequent hospitalization for congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

A randomized trial of therapies for type 2 diabetes and coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Improved clinical outcomes associated with metformin in patients with diabetes and heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Metformin use in patients with diabetes mellitus and heart failure: friend or foe?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

SGLT1, a novel cardiac glucose transporter, mediates increased glucose uptake in PRKAG2 cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961402-1

7 January 2021

10.1016/S0140-6736(14)61402-1

Identifiers

DOI

1 reference

release_pu3oei2d5zb3zpj2q5yahnevz4

3 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/pu3oei2d5zb3zpj2q5yahnevz4

24 November 2022

mapped directly with Wikidata item

PubMed ID

26009231

1 reference

PubMed ID

26009231